evipedia.ai
← Back

Urolithin A for Health & Longevity

Evidence Review created on 09/30/2026 using AI4L / Opus 5.5

Also known as: UA, UroA, Uro-A, Mitopure, AMAZ-02, 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one

Motivation

Urolithin A is a compound that certain gut bacteria make from plant substances found in pomegranates, walnuts and berries. It is also sold as a purified oral supplement. Interest centers on a single idea: it appears to switch on a cleanup process that clears worn-out parts of the cell’s energy-producing machinery and replaces them with new ones, a process that tends to slow with age.

Only a minority of adults carry the gut bacteria needed to make meaningful amounts from food, which is why a ready-made supplement drew attention from people focused on healthy aging. The compound came to prominence after laboratory work in worms and mice, and it has since been tested in small human trials, mainly on muscle function and the immune system.

This review examines what the human and laboratory evidence shows about urolithin A for muscle health, healthy aging and longevity, who funded that evidence, what is known about its safety, and how it is used in practice by proactive, health-focused adults.

Benefits - Risks - Protocol - Conclusion

This section lists expert and academic overviews that discuss urolithin A in depth.

Content from Andrew Huberman and Chris Kresser was not included: their platforms mention urolithin A only briefly (guest remarks and a passing reference), without the in-depth discussion needed to qualify. Five items met the criteria, so none were added from lower-priority sources.

Grokipedia

  • Urolithin A

    An encyclopedic overview of urolithin A as a postbiotic (a beneficial compound made by gut microbes) from ellagitannins (plant polyphenols in pomegranates, walnuts and berries), its chemistry, proposed pathways and producer variability.

Examine

  • Urolithin A

    An independent, evidence-based summary page concluding that urolithin A supplementation may benefit muscle function and endurance; its research feed of individual study summaries is available to members only.

ConsumerLab

Systematic Reviews

This section lists systematic reviews and meta-analyses that include urolithin A.

No systematic review or meta-analysis addresses urolithin A’s principal risks; this side of the trade-off is represented only by the adverse-event summary within Kuerec et al., 2024.

Mechanism of Action

Urolithin A is formed in the colon when bacteria break down ellagic acid (a plant polyphenol released from ellagitannins).

  • Mitophagy: In cells, worms and rodents, urolithin A activates the PINK1/Parkin pathway (a damage sensor that tags faulty mitochondria for disposal), clearing worn-out mitochondria and prompting new ones (Ryu et al., 2016, co-authored by Amazentis, the supplement’s developer).
  • Energy signaling: In animal studies it activates AMPK (adenosine monophosphate-activated protein kinase, the cell’s energy-shortage sensor) and dampens mTOR (mechanistic target of rapamycin, a growth-promoting nutrient sensor), both of which favor autophagy (general cellular recycling) (systematic review: Tow et al., 2022).
  • Inflammation and gut lining: In mice it strengthens the gut barrier through AhR (aryl hydrocarbon receptor, a sensor for dietary and microbial molecules) and Nrf2 (a master switch for antioxidant defenses) (Singh et al., 2019).
  • Pharmacology: Selectivity is low: it acts on several pathways without one high-affinity target. Plasma levels peak about 6 hours after an oral dose; half-life is 17–22 hours. It is conjugated (chemically tagged for excretion) by UGT enzymes (uridine diphosphate-glucuronosyltransferases, gut and liver enzymes that attach a sugar tag) and sulfotransferases (sulfate-tagging enzymes), circulating mainly as a glucuronide (the sugar-tagged form), not primarily via CYP (cytochrome P450, the main drug-metabolizing liver enzymes) (Andreux et al., 2019, Amazentis-run). It reaches plasma and alters muscle gene expression; brain penetration is unmeasured.
  • Competing view: Modeling predicts tissue levels far below concentrations used in cell studies, questioning which mechanisms operate in people (Aichinger et al., 2023).

Historical Context & Evolution

Urolithin A had no original therapeutic use. Urolithins were first characterized as ellagic acid breakdown products in animals, and for decades researchers used them only as markers showing that someone had eaten pomegranates, walnuts or berries.

In the 2000s, food scientists in Spain showed that people produce urolithins only when their gut bacteria can, defining urolithin metabotypes (distinct bacterial production profiles) and linking them mainly to age (Cortés-Martín et al., 2018). This helped explain why pomegranate studies gave inconsistent results.

Interest for health optimization began in 2016, when researchers at the Swiss Federal Institute of Technology in Lausanne and its spin-off Amazentis reported that urolithin A triggers mitophagy, extends worm lifespan and improves endurance in aged mice (Ryu et al., 2016). Amazentis then filed a GRAS (generally recognized as safe) notice with the FDA (US Food and Drug Administration), which raised no questions in 2018, ran the first human trials and launched the consumer ingredient Mitopure under its Timeline brand.

What followed was mixed. Company-funded trials reported better muscle endurance, strength and blood markers, but several primary endpoints, such as walking distance and muscle energy production, were missed. Independent pharmacokinetic modeling (simulating how the body absorbs and clears a compound) questioned whether tissue levels reach active concentrations (Aichinger et al., 2023), while a 2025 immune trial co-authored by Amazentis added supportive cellular data (Denk et al., 2025). The current standing rests on a small, mostly sponsor-funded evidence base that is developing in both directions rather than a settled verdict.

Expected Benefits

For health-focused adults who already exercise and eat well, the practical question is whether urolithin A adds anything on top of those habits; most trial participants were sedentary, untrained or older, and nearly all trials were funded by Amazentis, the ingredient’s developer.

High 🟩 🟩 🟩

Muscle Endurance and Strength

Urolithin A is proposed to improve muscle function by renewing muscle mitochondria. In 66 adults aged 65–90, 1,000 mg daily for 4 months increased hand and leg muscle endurance (Liu et al., 2022); in 88 middle-aged adults, 500–1,000 mg raised leg strength (Singh et al., 2022); resistance-trained men showed similar gains (Zhao et al., 2024). The first two were Amazentis-funded and missed their primary endpoints. Net reading: consistent secondary signals across small trials, not yet a confirmed primary effect.

Magnitude: Leg (hamstring) strength about 12% higher than placebo after 4 months of 500–1,000 mg daily; hand-muscle contractions to fatigue rose by 95 versus 12 with placebo at 2 months.

Medium 🟩 🟩

Faster Recovery After Strenuous Exercise

In a trial of 42 highly trained male runners, 1,000 mg daily for 4 weeks lowered perceived exertion and blood CK (creatine kinase, an enzyme released from damaged muscle) after a time trial in a 22-runner subset, while muscle biopsies showed reduced inflammatory signaling (Whitfield et al., 2025). CK after weekly downhill runs did not differ from placebo, and race performance did not improve. The trial was co-authored by Amazentis and Nestlé Health Science staff, and a single trial in young men limits generalization to older adults.

Magnitude: After a 3,000 m time trial at 4 weeks on 1,000 mg daily, total post-race CK release fell with urolithin A (Cohen’s d = 0.81, a standardized effect size where 0.8 counts as large) but not with placebo (d = 0.40); perceived exertion also fell with urolithin A (d = 0.84), a significant difference from placebo.

Low 🟩

Walking Capacity and Aerobic Fitness ⚠️ Conflicted

Walk distance and peak oxygen uptake (aerobic fitness) trended upward in older and middle-aged adults without beating placebo; trained runners saw no time-trial gain (Whitfield et al., 2025). An independent pilot in adolescent soccer players improved endurance (Monsalve Acevedo et al., 2025). Net reading: a possible small, unconfirmed effect.

Magnitude: Pooled six-minute walk gain of 17 m versus placebo, 95% CI (confidence interval, the plausible range) −5 to +39 m, low certainty (Dao et al., 2026).

Blood Vessel Function

Urolithin A may improve endothelial function (the artery lining’s ability to widen with blood flow). In 36 non-producers taking 10 or 50 mg daily for 12 weeks, it did not beat placebo (Nishimoto et al., 2022, DAICEL Corporation co-authored). Gains appeared only with poor baseline values.

Magnitude: No significant between-group change in flow-mediated dilation (an ultrasound test of artery widening); improvement was confined to participants with poor baseline values, and the trial reports no outcome figure for that subgroup.

Speculative 🟨

Lower Systemic Inflammation ⚠️ Conflicted

CRP (C-reactive protein, an inflammation marker) fell in longer healthy-adult trials (Zhao et al., 2024) but not a small 4-week heart-failure trial (Jamialahmadi et al., 2024). Net reading: modest reduction, unknown relevance.

Cardiovascular Risk Markers ⚠️ Conflicted

Ceramides (fat molecules predicting heart events) fell with 1,000 mg (Liu et al., 2025, Amazentis co-authored); HDL (“good” cholesterol) rose without cardiac benefit in heart failure (Jamialahmadi et al., 2024). Net reading: marker shifts only.

Immune Rejuvenation

In 50 middle-aged adults over 4 weeks, 1,000 mg expanded naive-like CD8 T cells (fresh “killer” immune cells) and boosted their fat-burning capacity (Denk et al., 2025). Amazentis co-authored; cell markers only, no infection outcomes.

Mitochondrial Renewal in Human Muscle

Trials show higher mitochondrial gene expression, mitophagy-related proteins and lower acylcarnitines (fat-burning byproducts) (Andreux et al., 2019). These are unvalidated biomarkers, and muscle energy production did not change.

Lifespan Extension

Urolithin A extended lifespan in worms and improved endurance in aged mice (Ryu et al., 2016). No mammalian lifespan study or human longevity outcome exists; the basis is animal work only.

Joint Health

In mice with osteoarthritis, urolithin A reduced cartilage loss, joint inflammation and pain, and improved mitochondria in human cartilage cells (D’Amico et al., 2022, Amazentis-run). The basis is animal and cell work only.

Brain Health and Cognition

In Alzheimer’s-model mice, urolithin A improved memory and restored mitophagy and lysosomal function (cellular waste disposal) (Hou et al., 2024). The basis is animal work only; human trials are under way.

Gut Barrier Integrity

In mice, urolithin A tightened the gut lining and reduced colitis (colon inflammation) via AhR and Nrf2 signaling (Singh et al., 2019). No human gut-barrier trial exists; the basis is animal work only.

Kidney Protection

A systematic review of 41 animal studies reported that urolithin A protected the kidneys across injury models (Tow et al., 2022). No human kidney outcome trial exists; the basis is animal work only.

Metabolic Health

The same systematic review of animal studies reported activity against metabolic disorders (Tow et al., 2022); a human glucose-metabolism trial is under way. The basis is animal work only.

Eye Health

In a mouse model of late-stage age-related macular degeneration (an aging-related loss of central vision), urolithin A preserved retinal cells and visual function (Jiménez-Loygorri et al., 2024). The basis is animal and cell work only.

Skin Aging

In aged human skin cells, urolithin A raised collagen (the skin’s main structural protein) and lowered a collagen-degrading enzyme (Liu et al., 2019). No human skin trial exists; the basis is cell work only.

Anticancer Activity

In fifteen cell-culture studies, urolithin A slowed colorectal cancer cell growth and spread (Francisco et al., 2026). No human cancer outcome exists; the basis is laboratory work only, and a prostate-cancer trial is under way.

Benefit-Modifying Factors

  • Natural producer status: About 40% of adults convert pomegranate compounds into meaningful urolithin A. Direct supplementation gave more than six-fold higher exposure than pomegranate juice, so non-producers have the most to gain (Singh et al., 2022, Amazentis-run).
  • Genetic polymorphisms: No gene variant has been shown to modify benefit. Variants in PINK1 or PRKN (the Parkin gene) impair mitophagy, and UGT1A1 variants (the enzyme that tags bilirubin and drugs for excretion) could alter conjugation; both remain untested.
  • Baseline biomarkers and fitness: Signals were strongest in sedentary or lower-functioning adults; an artery-function improvement appeared only in people with poor baseline values (Nishimoto et al., 2022). Highly trained athletes showed recovery rather than performance gains (Whitfield et al., 2025).
  • Sex: The older-adult trial was 76% women (Liu et al., 2022), the middle-aged trial mixed and athlete trials all men. No trial has analyzed sex differences, so any difference in benefit is unknown.
  • Age: Adults aged 65–90 gained endurance but not walking distance (Liu et al., 2022); middle-aged adults gained strength (Singh et al., 2022). Natural production changes with age, making supplementation more relevant later in life; people over 90 are unstudied.
  • Pre-existing conditions: Heart failure with reduced ejection fraction (weakened heart pumping) showed no benefit in one small trial (Jamialahmadi et al., 2024). Obesity, gut dysbiosis (imbalanced gut bacteria) and recent antibiotics lower natural production, increasing the relevance of direct supplementation.

Potential Risks & Side Effects

For this audience, the practical risks are less about documented harms, of which there are few, than about product quality, unknown long-term effects and theoretical concerns in specific medical situations.

High 🟥 🟥 🟥

No risk reaches High: human safety data consist of small randomized trials lasting up to four months that recorded no adverse event occurring more often with urolithin A than with placebo.

Medium 🟥 🟥

No risk reaches Medium: no single trial or observational dataset has documented a clinical adverse event attributable to urolithin A.

Low 🟥

Mild Non-Specific Adverse Events

Trials record diverse, mostly mild adverse events at rates similar to placebo; a systematic review judged adverse events mild or moderate and unrelated (Kuerec et al., 2024). Data span at most four months and mostly company-funded trials.

Magnitude: 16 versus 15 treatment-emergent adverse events with urolithin A versus placebo over 4 months, with no serious events (Liu et al., 2022).

Speculative 🟨

Hormonal (Estrogen-Receptor) Activity

In breast-cancer cells, urolithin A bound estrogen receptors and showed weak estrogenic and antiestrogenic effects (Larrosa et al., 2006). The basis is laboratory-only; relevance at supplement doses is unknown.

Support of Established Tumors

Increased cellular recycling can help established cancer cells survive stress. This is mechanistic reasoning only; laboratory data mostly show anti-tumor effects, and cancer trials are ongoing.

High-Dose Toxicity Questions

A toxicologist noted similarity to the fungal toxin alternariol (Aichinger, 2021). Amazentis-run rat studies found no genotoxicity (DNA damage) or organ toxicity (Heilman et al., 2017). The basis is structural analogy and animal toxicology only.

Unknown Long-Term Effects

No human trial exceeds four months, so the effects of years of continuous mitophagy stimulation are unknown. The basis is an absence of data rather than an observed signal.

Risk-Modifying Factors

  • Genetic polymorphisms: Reduced-function UGT1A1 variants, as in Gilbert syndrome (harmless mild bilirubin elevation), could theoretically slow conjugation and raise exposure. No study has tested this, and no other genetic risk modifiers are known.
  • Baseline biomarkers: Trials excluded people with abnormal liver enzymes or reduced eGFR (estimated glomerular filtration rate, a kidney-function measure), so safety in these states is unknown. Baseline values make later changes interpretable.
  • Sex: No sex-specific adverse events have been reported. Because of laboratory estrogen-receptor binding, women with hormone-sensitive conditions and pregnant or breastfeeding women remain untested groups.
  • Pre-existing conditions: Hormone-sensitive cancers, active cancer treatment, organ transplantation with immune suppression and severe liver or kidney disease are unstudied; the immune and estrogen-receptor effects make these theoretical concerns.
  • Age: Trials included adults up to 90 without age-specific harms, though frail adults over 80 are underrepresented. Adolescents were studied only in one 6-week pilot in soccer players (Monsalve Acevedo et al., 2025).

Key Interactions & Contraindications

  • Immunosuppressants (tacrolimus, cyclosporine, mycophenolate): Caution, theoretical. Urolithin A shifts immune-cell composition and function, which could counteract intended immune suppression. No cases are reported. Known mitigation: prior approval by the prescribing transplant or rheumatology team.
  • Endocrine cancer therapies (tamoxifen; aromatase inhibitors, drugs blocking estrogen production, such as anastrozole and letrozole): Caution, theoretical. Laboratory estrogen-receptor binding raises a question of interference with hormone therapy; no human data exist. Known mitigation: oncologist review before use.
  • Immune checkpoint inhibitors (cancer drugs that release immune brakes, such as pembrolizumab and nivolumab): Monitor, investigational. Urolithin A is being tested alongside these drugs; effects on efficacy and immune side effects are unknown. Known mitigation: oncology supervision or use within trials.
  • Drugs cleared by glucuronidation (mycophenolate, lamotrigine, valproate): Monitor, theoretical. Shared UGT enzymes could modestly alter drug levels, though no interaction has been documented. Known mitigation: drug-level monitoring where routinely available.
  • Antibiotics (amoxicillin, ciprofloxacin, doxycycline): Minimal concern. Antibiotics suppress the bacteria that make urolithin A from food, lowering natural production; direct supplementation bypasses this. Consequence: reduced food-derived levels only.
  • Over-the-counter medications (NSAIDs, nonsteroidal anti-inflammatory pain relievers such as ibuprofen and naproxen; acetaminophen; antacids such as calcium carbonate and magnesium hydroxide): No documented interactions. Acetaminophen is partly glucuronidated, so theoretical competition exists at high doses. Severity: monitor only; no clinical consequence described.
  • Food-derived precursors (pomegranate extract, ellagic acid supplements, walnuts): Additive, monitor. In natural producers these add urolithin A on top of the supplement; the consequence is higher total exposure with no known harm. Known mitigation: counting combined intake from all sources.
  • Other mitochondrial or autophagy supplements (spermidine, nicotinamide riboside, NMN (nicotinamide mononucleotide), resveratrol): Additive mechanism, caution. Overlapping effects on mitochondrial turnover and energy sensing; combined benefit or harm is untested. Known mitigation: introducing one agent at a time to attribute effects.
  • Probiotics and synbiotics (probiotics combined with fiber or polyphenol “food” for the bacteria, such as DS-01): Additive, monitor. A multi-strain synbiotic raised natural urolithin A production in a trial (Napier et al., 2025); the consequence is higher combined exposure with no known harm.
  • Exercise training: Potentiating (favorable). Exercise also stimulates mitophagy, and trials in trained athletes showed no blunting of training gains (Zhao et al., 2024). Severity: none; the combination is the context used in athlete trials.

Populations who should avoid Urolithin A:

  • Pregnant or breastfeeding women (no safety data)
  • Children and adolescents under 18 years (only one 6-week pilot in 17-year-olds)
  • People with estrogen-receptor-positive breast, endometrial or other hormone-sensitive cancers, especially during endocrine therapy (theoretical concern)
  • Solid-organ transplant recipients on immunosuppressants (theoretical concern)
  • Severe liver impairment (Child-Pugh Class C, the most severe liver-disease category) or eGFR below 30 mL/min/1.73 m² (unstudied)
  • Known hypersensitivity to urolithin A or product ingredients

Risk Mitigation Strategies

  • Verified product identity: Products with a certificate of analysis from an ISO/IEC 17025-accredited laboratory (international standard for testing labs) mitigate the risk of receiving little or no urolithin A; 6 of 10 tested products failed label claims.
  • Graded start: Beginning at 500 mg daily for 2–4 weeks before any increase to 1,000 mg limits possible mild adverse events such as digestive discomfort and shows individual tolerance.
  • Dosing with a meal: Taking the daily dose with breakfast or another meal is used to reduce gastrointestinal discomfort; no trial suggests loss of absorption with food.
  • Dose ceiling: Staying at or below 1,000 mg daily keeps exposure within the longest-tested human range, mitigating unknown high-dose toxicity; only single doses up to 2,000 mg have been studied (Andreux et al., 2019).
  • Laboratory safety checks: ALT and AST (liver enzymes) plus creatinine and eGFR at baseline, 3 months, then every 6–12 months detect unexpected liver or kidney effects, addressing unknown long-term safety.
  • Specialist review in high-risk settings: Oncology or transplant team review before use mitigates theoretical estrogen-receptor and immune interactions in hormone-sensitive cancer, checkpoint-inhibitor therapy or immunosuppression.
  • Periodic reassessment: Reviewing continued use every 6–12 months against measured strength, fitness and laboratory results limits open-ended exposure to a compound with no data beyond four months.

Therapeutic Protocol

  • Standard dose: 500–1,000 mg urolithin A once daily, the range tested in human trials; 500 mg is the usual commercial serving and 1,000 mg the dose in most performance trials (Singh et al., 2022).
  • Practitioner approaches: Rhonda Patrick describes 500–1,000 mg daily taken continuously with food; physician Gabrielle Lyon, on the Huberman Lab podcast, describes 500–1,000 mg alongside creatine and protein for muscle health. Timeline popularized the 500 mg daily serving.
  • Food-precursor approach: Natural producers can generate urolithin A from pomegranate juice, walnuts or berries; exposure is roughly six-fold lower than supplementation. Producer-status tests identify who can use this route; researchers in Spain popularized the metabotype approach.
  • Exercise-first approach: Brian Kennedy, on Peter Attia’s podcast, ranks muscle, strength and fitness as the strongest healthspan predictors; in this approach training, which also stimulates mitophagy, is the foundation and urolithin A an optional add-on.
  • Time of day: Trials dosed once daily, usually in the morning with breakfast; no trial compared timing. The long half-life makes timing flexible.
  • Half-life: Plasma levels peak about 6 hours after a dose; the parent compound’s half-life is 17–22 hours and its conjugates persist longer, supporting stable levels with once-daily dosing (Andreux et al., 2019).
  • Single versus split dosing: A single daily dose is standard. The heart-failure trial used 500 mg twice daily without advantage (Jamialahmadi et al., 2024), and the long half-life gives no pharmacokinetic reason to split.
  • Genetic polymorphisms: No genotype-guided dosing exists. Carriers of reduced-function UGT1A1 variants (Gilbert syndrome) are a theoretical reason to stay at 500 mg until tolerance is clear.
  • Sex: Doses are identical for women and men; no trial reported a sex-specific response or dose requirement.
  • Age: Adults aged 65–90 used 1,000 mg (Liu et al., 2022); middle-aged adults gained strength at 500 mg. No age-based adjustment has been tested; older adults, whose natural production is less reliable, depend more on supplementation.
  • Baseline biomarkers: Non-producer status, low fitness, elevated CRP or low grip strength mark those with the most room to improve; highly fit athletes showed smaller performance effects.
  • Pre-existing conditions: Heart failure showed no benefit at 1,000 mg daily; obesity and metabolic conditions are under study. Liver or kidney impairment lacks dosing data, so trial doses cannot be assumed appropriate there.
  • Duration before judging response: Endurance changes appeared at 2 months (Liu et al., 2022) and strength changes at 4 months (Singh et al., 2022), so a 4-month course matches the trial evidence.

Discontinuation & Cycling

  • Intended duration: Marketed for ongoing, lifelong use, yet human data cover only four months; long-term use therefore rests on extrapolation from short trials and animal studies.
  • Withdrawal effects: None reported. Urolithin A is not habit-forming, and no rebound effects are described; plasma levels fall over several days after stopping.
  • Tapering: Not required. Trials stopped supplementation abruptly without reported problems.
  • Cycling: No evidence supports cycling for maintaining efficacy, and no trial has compared continuous with intermittent use. Rhonda Patrick describes continuous use.
  • Persistence of effects: Whether muscle or immune changes persist after stopping is unknown; no trial measured outcomes after a washout period.

Sourcing and Quality

  • Label accuracy: Independent testing by SuppCo, a supplement-tracking company that also sells a certification program, found 6 of 10 popular urolithin A products delivered little or none of their labeled dose (SuppCo Tested – Don’t Trust the Label: Urolithin A Supplements Exposed).
  • Counterfeits: In July 2026 a US federal court permanently barred 19 online sellers from marketing fake urolithin A products after a lawsuit by Timeline, the manufacturer, underscoring the counterfeit problem on large marketplaces.
  • Trial-tested ingredient: Nearly all human trials used Mitopure, a high-purity synthetic urolithin A from Amazentis, sold as Timeline softgels and powders and licensed to other brands; results may not transfer to untested products.
  • What to look for: Stated milligrams of urolithin A (not “precursor” or extract equivalents), a batch certificate of analysis, third-party certification where offered, and softgel or food-matrix formats matching the forms used in trials.
  • Precursor products: Pomegranate-extract “urolithin precursor” supplements work only in natural producers and give far lower exposure; ConsumerLab reviews products such as Timeline Mitopure, Pure Encapsulations Renual, CodeAge Liposomal Urolithin A and Neurogan Pro+.
  • Formulation claims: Liposomal and “enhanced absorption” versions lack published human comparisons; Amazentis-run bioavailability studies of its own formulations have been registered but not all published.

Practical Considerations

  • Time to effect: Immune-cell changes appeared within 4 weeks (Denk et al., 2025), muscle endurance changes at 2 months and strength changes at 4 months; improvements in how daily activities feel are not established in trials.
  • Common pitfalls: Buying cheap, untested products; assuming pomegranate juice substitutes for supplementation in non-producers; judging results after a few weeks; and treating urolithin A as a replacement for exercise rather than an add-on.
  • Regulatory status: In the US urolithin A is sold as a dietary supplement and has an FDA GRN No. 791: Urolithin A “no questions” letter for foods up to 500–1,000 mg per serving; it is not an approved drug.
  • Cost and accessibility: Trial-grade products cost roughly US$60–120 per month, and no insurer or health system reimburses them. The main alternative, exercise, is low-cost, and no payer incentive shaping this evidence has been identified.
  • Conflicts of interest: Amazentis, which sells Mitopure, funded or co-authored most human trials and several reviews, so independent replication is limited.

Interaction with Foundational Habits

  • Sleep: No direct interaction is documented; trials report no sleep disruption. A trial pairing urolithin A with fisetin is testing effects on sleep quality (NCT06990256), so any potentiating effect remains unconfirmed. Morning dosing avoids any theoretical overlap with sleep.
  • Nutrition: Indirect, potentiating. Ellagitannin foods (pomegranate, walnuts, raspberries, pecans) add natural urolithin A in producers, and fiber-rich, diverse diets support producing bacteria. No known nutrient depletion; trial doses were taken with food.
  • Exercise: Potentiating. Both exercise and urolithin A stimulate mitophagy; trials in resistance-trained men and runners showed no blunting of adaptations (Whitfield et al., 2025), unlike some high-dose antioxidants. Timing relative to workouts has not been studied, and athlete trials dosed daily regardless of training.
  • Stress management: Indirect, direction unknown. No human data on cortisol or stress response exist; in chronically stressed mice it reduced anxiety-like behavior and stress-hormone levels (Di et al., 2025). Any benefit would be indirect, through lower inflammation and better exercise tolerance.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes reference points: a metabolic panel with liver enzymes and kidney function, high-sensitivity CRP, a lipid panel, optional plasma ceramides, and simple function tests such as grip strength and six-minute walk distance. Producer-status testing shows whether food alone yields urolithin A. Ongoing monitoring follows a cadence of baseline, 3 months and then every 6–12 months, repeating safety labs and function tests under identical conditions so that change reflects the intervention rather than test variability. Success is defined by improved or maintained strength, endurance and recovery alongside stable liver and kidney values; unchanged function after four months suggests little individual benefit. Because no biomarker is validated for urolithin A response, trends in function and inflammation carry more weight than any single value.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
hs-CRP Below 1.0 mg/L (functional target below 0.5 mg/L) Inflammation marker that fell in trials hs-CRP = high-sensitivity C-reactive protein. Conventional low-risk cutoff below 3.0 mg/L; no fasting needed; repeat if above 10 mg/L (acute illness)
ALT and AST ALT below 25 U/L; AST below 25 U/L Liver safety Conventional upper limits about 40–55 U/L; avoid strenuous exercise 48 hours before, as it raises AST; pair with GGT (gamma-glutamyl transferase, another liver enzyme)
Creatinine and eGFR eGFR above 90 mL/min/1.73 m² Kidney safety Conventional normal is above 60; pair with cystatin C (a muscle-independent kidney marker) in muscular people
Lipid panel with HDL HDL above 60 mg/dL; triglycerides below 100 mg/dL Cardiovascular context; HDL rose in one trial Conventional HDL at or above 40 mg/dL (men) and 50 mg/dL (women); conventional triglycerides below 150 mg/dL; fasting 10–12 hours
Plasma ceramides Low-risk CERT-2 score category (0–2); otherwise track change from own baseline Marker that fell with urolithin A CERT-2 = a ceramide-based cardiovascular risk score; specialized laboratory; fasting sample
Urolithin A producer status No established target; record producer versus non-producer Shows whether food alone yields urolithin A Measured in urine or dried blood spot after pomegranate juice or walnuts; not repeated routinely
Handgrip strength Men above 40 kg; women above 27 kg Tracks muscle strength response EWGSOP2 (European Working Group on Sarcopenia in Older People; sarcopenia = age-related muscle loss) low-strength cutoffs are below 27 kg (men) and 16 kg (women); same dynamometer (grip-strength device), best of three
Six-minute walk distance No universal target; track change from own baseline Tracks physical performance Same course and time of day; changes of about 20–30 m are commonly considered meaningful
VO2 max Above the 75th percentile for age and sex Tracks aerobic fitness VO2 max = maximal oxygen uptake; laboratory test or validated wearable estimate; test well rested

Qualitative markers:

  • Energy levels and daytime vitality
  • Exercise tolerance and perceived exertion during usual workouts
  • Recovery time and muscle soreness after strenuous sessions
  • Digestive comfort after starting or increasing the dose
  • Sleep quality
  • Frequency and duration of common infections

Emerging Research

  • Muscle strength confirmation: A 120-participant trial of Mitopure on muscle strength in healthy middle-aged adults (NCT07231783), recruiting and Amazentis-sponsored, could confirm or refute the strength signal as a primary endpoint.
  • Independent glucose metabolism trial: The US National Institute on Aging is running a 180-participant, triple-masked (participants, staff and analysts unaware of assignment) trial of urolithin A on glucose metabolism in adults 55 and older (NCT06274749), an important non-industry test.
  • Brain health: A 650-participant Amazentis trial of a brain supplement containing Mitopure on cognitive function (NCT07060898) and a 60-participant trial in early Alzheimer’s disease (NCT07842146) will test cognitive outcomes; a planned spinal-fluid study measures brain exposure (NCT07517913).
  • Cancer settings: The National Cancer Institute’s phase 2 URO-PRO trial in 90 men undergoing prostate removal (NCT06022822) and a 45-patient trial alongside checkpoint inhibitors (NCT07161310) will inform both anti-tumor hopes and tumor-safety questions.
  • Muscle disuse and obesity: A 24-participant trial of urolithin A with protein during leg immobilization, measuring muscle mitochondrial respiration (NCT05814705), and a completed 50-participant trial in middle-aged adults with obesity, measuring artery function (NCT05921266), await publication.
  • Evidence that could weaken the case: A meta-analysis found walking-distance effects statistically inconclusive with low certainty (Dao et al., 2026), and pharmacokinetic modeling suggests tissue levels may be too low for many laboratory effects (Aichinger et al., 2023).
  • Immune aging: Following the positive 4-week immune-cell trial (Denk et al., 2025), longer trials measuring vaccine response or infection rates would show whether cellular changes translate into clinical protection.
  • Personalized combinations: The PROMETHEUS protocol in Singapore tests tailored lifestyle and supplement combinations, including urolithin A, in 20 adults aged 50–80 (NCT07451496; Kuerec et al., 2026).

Conclusion

Urolithin A is a compound some gut bacteria make from pomegranates, walnuts and berries, now available as a purified supplement. Its appeal for longevity rests on one idea: helping cells clear out and replace worn-out energy-producing parts, a process that weakens with age.

The strongest human signal is for muscle endurance and strength, with a suggestion of faster recovery after hard exercise. These signals are consistent but modest, and they come from small, short trials that often missed their main goals. Effects on walking ability, fitness, inflammation, heart health, immune aging, joints, brain health and lifespan are uncertain or rest largely on animal and cell studies.

Short-term safety looks reassuring: side effects in trials were mild and no more common than with an inactive look-alike product. What remains unknown is how years of use affect the body, and there are theoretical concerns for people with hormone-sensitive cancers, people on drugs that deliberately suppress the immune system, and people with serious organ disease. Product quality is a practical risk, since many products on the market contain little of what their labels claim.

The evidence base is thin and heavily shaped by the company that developed and sells the main ingredient, which funded or co-authored most human studies. For active, health-focused adults already training and eating well, urolithin A is a plausible but unproven add-on, most relevant for people who cannot make it from food, with the size of any extra benefit still uncertain.

Top - Benefits - Risks - Protocol